Xconomy -- Aveo Pharmaceuticals, a Cambridge, MA-based company with a drug in late-stage development for advanced kidney cancer, said today that it has recruited biotech bigwig Henri Termeer, the outgoing chairman and CEO of biotech drug maker Genzyme, to join its board of directors. Termeer, who joined Genzyme in 1983 and built it into an industry standout, plans to step down from his CEO role at the company now that French drug giant Sanofi-Aventis (NYSE:SNY) has completed its $20.1 billion buyout of the biotech firm.
